{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:07:18Z","timestamp":1790165238118,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.imj.2026.100277","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:57:04Z","timestamp":1785394624000},"page":"100277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of human antibody specific to the spike glycoprotein subunit 2 of SARS-CoV-2 and characterization of its broad-spectrum neutralizing activity"],"prefix":"10.1016","volume":"5","author":[{"given":"Ying","family":"Chi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyue","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunbiao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imj.2026.100277_bib0001","unstructured":"Tracking SARS-CoV-2 variants. World Health Organization. Accessed December 5, 2025. https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants."},{"issue":"23","key":"10.1016\/j.imj.2026.100277_bib0002","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/j.scib.2023.09.048","article-title":"Classification of five SARS-CoV-2 serotypes based on RBD antigenicities","volume":"68","author":"Hu","year":"2023","journal-title":"Sci Bull"},{"issue":"6","key":"10.1016\/j.imj.2026.100277_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(23)00411-1","article-title":"The Omicron BA.2.86 subvariant as a new serotype of SARS-CoV-2","volume":"5","author":"Du","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.imj.2026.100277_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105634","article-title":"SARS-CoV-2 serotyping based on spike antigenicity and its implications for host immune evasion","volume":"114","author":"Ruan","year":"2025","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.imj.2026.100277_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101124","article-title":"Defining the serotypes of SARS-CoV-2 subvariants up to December, 2024","volume":"6","author":"Du","year":"2025","journal-title":"Lancet Microbe"},{"issue":"4","key":"10.1016\/j.imj.2026.100277_bib0006","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/HAB-200429","article-title":"COVID-19: significance of antibodies","volume":"28","author":"Assadiasl","year":"2020","journal-title":"Hum Antibodies"},{"issue":"6483","key":"10.1016\/j.imj.2026.100277_bib0007","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"issue":"6491","key":"10.1016\/j.imj.2026.100277_bib0008","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1126\/science.abb7269","article-title":"A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.imj.2026.100277_bib0009","article-title":"Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses","volume":"2","author":"Ladner","year":"2021","journal-title":"Cell Rep Med"},{"issue":"10","key":"10.1016\/j.imj.2026.100277_bib0010","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41423-020-00523-5","article-title":"Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients","volume":"17","author":"Li","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"6559","key":"10.1016\/j.imj.2026.100277_bib0011","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1126\/science.abj3321","article-title":"Broad betacoronavirus neutralization by a stem helix-specific human antibody","volume":"373","author":"Pinto","year":"2021","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.imj.2026.100277_bib0012","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.str.2022.06.004","article-title":"Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability","volume":"30","author":"Shi","year":"2022","journal-title":"Structure"},{"issue":"3","key":"10.1016\/j.imj.2026.100277_bib0013","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/00063030-200721030-00002","article-title":"Epitope mapping: the first step in developing epitope-based vaccines","volume":"21","author":"Gershoni","year":"2007","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.imj.2026.100277_bib0014","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0022-2836(91)90498-U","article-title":"By-passing immunization Human antibodies from V-gene libraries displayed on phage","volume":"222","author":"Marks","year":"1991","journal-title":"J Mol Biol"},{"issue":"3","key":"10.1016\/j.imj.2026.100277_bib0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nbt0396-309","article-title":"Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library","volume":"14","author":"Vaughan","year":"1996","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.imj.2026.100277_bib0016","series-title":"COVID-19 Cases | WHO COVID-19 dashboard","year":"2026"},{"key":"10.1016\/j.imj.2026.100277_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-042420-113838","article-title":"SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment","volume":"73","author":"Li","year":"2022","journal-title":"Annu Rev Med"},{"issue":"3","key":"10.1016\/j.imj.2026.100277_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247640","article-title":"Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma","volume":"16","author":"Tso","year":"2021","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.imj.2026.100277_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac517","article-title":"Evaluation of bebtelovimab for treatment of covid-19 during the SARS-CoV-2 Omicron Variant era","volume":"9","author":"McCreary","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.imj.2026.100277_bib0020","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s40265-022-01731-1","article-title":"Tixagevimab + cilgavimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.imj.2026.100277_bib0021","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","article-title":"Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies","volume":"182","author":"Barnes","year":"2020","journal-title":"Cell"},{"issue":"37","key":"10.1016\/j.imj.2026.100277_bib0022","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq8276","article-title":"Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response","volume":"8","author":"Dickey","year":"2022","journal-title":"Sci Adv"},{"issue":"4","key":"10.1016\/j.imj.2026.100277_bib0023","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.kint.2022.01.016","article-title":"Breakthrough Omicron COVID-19 infections in patients receiving the REGEN-Cov antibody combination","volume":"101","author":"Flahault","year":"2022","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.imj.2026.100277_bib0024","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMc2207519","article-title":"Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants","volume":"387","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.imj.2026.100277_bib0025","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41467-021-21968-w","article-title":"A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"issue":"6520","key":"10.1016\/j.imj.2026.100277_bib0026","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4250","article-title":"Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity","volume":"370","author":"Shrock","year":"2020","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.imj.2026.100277_bib0027","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","article-title":"Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses","volume":"23","author":"Chen","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.imj.2026.100277_bib0028","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2220582","article-title":"SARS-CoV-2 spike S2-specific neutralizing antibodies","volume":"12","author":"Li","year":"2023","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"10.1016\/j.imj.2026.100277_bib0029","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41392-023-01472-x","article-title":"Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.imj.2026.100277_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012757","article-title":"SARS-CoV-2 Omicron variations reveal mechanisms controlling cell entry dynamics and antibody neutralization","volume":"20","author":"Qing","year":"2024","journal-title":"PLoS Pathog"},{"issue":"7","key":"10.1016\/j.imj.2026.100277_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010691","article-title":"Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody","volume":"18","author":"Piepenbrink","year":"2022","journal-title":"PLoS Pathog"},{"issue":"637","key":"10.1016\/j.imj.2026.100277_bib0032","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abi9215","article-title":"A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection","volume":"14","author":"Zhou","year":"2022","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.imj.2026.100277_bib0033","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s42003-022-03262-7","article-title":"Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit","volume":"5","author":"Hurlburt","year":"2022","journal-title":"Commun Biol"},{"issue":"2","key":"10.1016\/j.imj.2026.100277_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110210","article-title":"Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern","volume":"38","author":"Li","year":"2022","journal-title":"Cell Rep"}],"container-title":["Infectious Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772431X26000432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772431X26000432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:53:53Z","timestamp":1790164433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772431X26000432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2772431X26000432"],"URL":"https:\/\/doi.org\/10.1016\/j.imj.2026.100277","relation":{},"ISSN":["2772-431X"],"issn-type":[{"value":"2772-431X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of human antibody specific to the spike glycoprotein subunit 2 of SARS-CoV-2 and characterization of its broad-spectrum neutralizing activity","name":"articletitle","label":"Article Title"},{"value":"Infectious Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imj.2026.100277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of Tsinghua University Press.","name":"copyright","label":"Copyright"}],"article-number":"100277"}}